z-logo
Premium
Disposition of Intravenous Propylthiouracil
Author(s) -
GILES H. G.,
ROBERTS E. A.,
ORREGO H.,
SELLERS E. M.
Publication year - 1981
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1981.tb05651.x
Subject(s) - free fraction , propylthiouracil , volume of distribution , chemistry , pharmacokinetics , urine , clearance , liter , endocrinology , reabsorption , medicine , urinary system , renal physiology , renal function , urology , kidney , thyroid
Propylthiouracil was administered to 10 healthy, male volunteers by a short intravenous infusion. Plasma and urinary drug concentrations were determined by a specific high‐performance liquid chromatography assay, and protein binding was determined by equilibrium dialysis. After infusion, the plasma concentrations declined biexponentially, and the following median parameters (and ranges) were determined: clearance 273.5 ml/min (159.5–377.8 ml/min); free drug clearance, 1537.7 ml/min (985.9–1927.3 ml/min); apparent volume of distribution, 28.0 liters (22.7–44.4 liters); apparent elimination half‐life, 1.28 hr (0.88–2.05 hr); k 21 , 3.12 hr −1 (1.06–5.36 hr −1 ); α 7.34 hr −1 (1.94–25.03 hr −1 ); V c 9.40 liters (5.16–18.58 liters). In urine, only 1.28 per cent (0.03–2.01 per cent) of the administered dose was recovered over 24 hours as unchanged drug. The ratio (1.2 per cent) of urinary clearance (3.2 ml/min) to plasma clearance is far less ( P < 0.001) than the free fraction in plasma (median 18.2 percent, range 16.2–20.2 per cent) and this suggests that there is significant renal tubular reabsorption of propylthiouracil. In healthy subjects, both intraindividual and interindividual variation in protein binding is modest, and free drug clearance can be predicted from total drug clearance ( y = 257.6 + 4.56 x, r = 0.95, P < 0.001).

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here